Pemafibrate, a novel selective PPARα modulator, amends NASH histological features in mice [123] and serum alanine aminotransferase (ALT) in NASH patients with dyslipidemia [124]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.